FDAnews
www.fdanews.com/articles/130963-immunogen-licenses-technology-to-novartis-in-245-million-deal

ImmunoGen Licenses Technology to Novartis in $245 Million Deal

October 11, 2010
ImmunoGen Inc. has agreed to work with Novartis on targeted anticancer therapeutics developed using ImmunoGen’s Targeted Antibody Payload technology, in a deal potentially worth nearly $250 million — and potentially much more.
Mass High Tech